Nintedanib receives positive CHMP opinion in European Union for the treatment of IPF
21 November 2014 | By Boehringer Ingelheim
Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF).